Constitutional asymmetry and pharmaceutical policy-making in the European Union

Journal of European Public Policy

Volumn 12, Issue 4, 2005, Pages 687-709

  Permanand, Govin ^a   Mossialos, Elias ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

Constitutional asymmetry; European Union; Pharmaceuticals; Policy making; Regulation; Single market

Indexed keywords

EID: 22944492702     PISSN: 13501763     EISSN: None     Source Type: Journal    
DOI: 10.1080/13501760500160607     Document Type: Article

References (35)

1. Abraham, J. and Lewis, G. (2000) Regulating Medicines in Europe: Competition, Expertise and Public Health, London: Routledge.
2. Albedo (1991) 'Transparency Directive II - sequel or remake?', Pharmaceutical Technology Europe September: 12-20.
3. BEUC (1991) 'Longer patent protection periods for medicines: a blank cheque for the pharmaceutical industry?', BEUC press release, Brussels: Bureau Européen des Unions de Consommateurs.
4. BEUC (1994) BEUC's Opinion on the Outlines of an Industrial Policy for the Pharmaceutical Sector in the EC, Brussels: Bureau Européen des Unions de Consommateurs.
5. Brittan, L. (1992) 'Making a reality of the Single Market: pharmaceutical pricing and the European Economic Community'. Speech to the Institute of Economic Affairs Conference on Pharmaceutical Policies in Europe, London (December 1992).
6. Cameron McKenna (2000) Evaluation of the Operation of Community Procedures for the Authorization of Medicinal Products - Report Carried Out on Behalf of the European Commission, Brussels: DG Enterprise, Commission of the European Communities.
7. CEC (1988) Compilation of Comments Received on Outstanding White Paper Proposals for Completion of the Internal Market in the Pharmaceutical Sector. Memorandum III/ 3785/88, Brussels: Commission of the European Communities.
8. CEC (1990) Proposal for a Council Regulation (EEC) Laying Down Community Procedures for the Authorization and Supervision of Medicinal Products for Human and Veterinary Use and Establishing a European Agency for the Evaluation of Medicinal Products. COM (1990) 283 Final - SYN 309, 14 November 1990. Official Journal of the European Communities C330/90: 1.
9. CEC (1993) Commission of the European Communities. Background Report: The European Medicines Evaluation Agency. ISEC/B33/93.
10. CEC (1995) 'Inauguration of the European Agency for the Evaluation of Medicinal Products', press release DN: IP/95/64, 1995-01-26, Brussels: Commission of the European Communities.
11. CECG (1993) Pharmaceutical in the Single Market. Consumers in the European Community Group.
12. Chapman, S., Durieux, P. and Walley, T. (2004) 'Good prescribing practice', in E. Mossialos, M. Mrazek and T. Walley (eds), Regulating Pharmaceutical in Europe: Striving for Efficiency, Equity and Quality, Maidenhead: Open University Press.
13. COM (1993) 'Commission Communication to the Council and Parliament on the outlines of an industrial policy for the pharmaceutical sector in the European Community'. COM (93) 718, 2 March 1994.
14. COM (2001) Proposal for a Regulation of the European Parliament and of the Council Laying Down Community Procedures for the Authorization and Supervision of Medicinal Products for Human and Veterinary Use and Establishing a European Agency for the Evaluation of Medicinal Products. COM/2001/0404 final.
15. COM (2003) 383 Final of 1 July 2003. Communication from the Commission to the Council, European Parliament, the Economic and Social Committee, and the Committee of the Regions: A Stronger European-based Pharmaceutical Industry for the Benefit of the Patient - A Call for Action.
16. EFPIA (2002) The Pharmaceutical Industry in Figures - Key Data (2002 Update), Brussels: European Federation of Pharmaceutical Industries and Associations.
17. EMEA (1996) First General Report on the Activities of the European Agency for the Evaluation of Medicinal Products 1995. EMEA/MB/065/95.
18. Furniss, J. (1997) 'The Bangemann round table: a beginning and not an end', Eurohealth 3(1): 27-8.
19. G10 (2002) High Level Group on Innovation and Provision of Medicines: recommendations for action, Enterprise Directorate-General, Brussels: Commission of the European Communities.
20. Garattini, S. and Bertele', V. (2001) 'Adjusting Europe's drug regulation to public health needs', The Lancet 358: 64-7.
21. Generics Bulletin (2004) 'European revisions offer new freedoms for generics', 16 January 2004: 18-21.
22. Hancher, L. (1990) 'The European pharmaceutical market: problems of partial harmonization', European Law Review 15: 9-33.
23. Hood, C. (1994) Explaining Economic Policy Reversah, Buckingham: Open University Press.
24. Majone, G. (ed.) (1996) Regulating Europe, London: Routledge.
25. Matthews, D. and Wilson, C. (1998) 'Pharmaceutical regulation in the single European market', Medicine and Law 17: 401-27.
26. Orzack, L. (1996) 'Professionals, consumers, and the European medicines agency: policy-making in the European Union', Current Research on Occupations and Professions 9: 9-29.
27. Permanand, G. (2002) 'Regulating under constraint: the case of EU pharmaceutical policy'. Ph.D. dissertation. University of London: London School of Economics and Political Science.
28. Permanand, G. and Altenstetter, C. (2004) 'The politics of pharmaceuticals in the European Union', in E. Mossialos, M. Mrazek and T. Walley (eds), Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality, Maidenhead: Open University Press.
29. PhRMA (2002) PhRMA Industry Profile 2002, Washington, DC: Pharmaceutical Research and Manufacturers of America.
30. Sauer, F. (2000) 'New drugs in the global economy'. Speech to the Graduate School of Public Health, University of Pittsburgh, 13 November 2000.
31. Scharpf, F. (2002) The European Social Model: Coping with the Challenges of Diversity, Max-Planck-Institut für Gesellschaftsforschung Working Paper 02/08. Köln: MPIfG.
32. Scherer, F. (1996) Industry Structure, Strategy, and Public Policy, New York: HarperCollins College Publishers.
33. Shechter, Y. (1998) 'Interests, strategies, and institutions: lobbying in the pharmaceutical industry of the European Union'. Ph.D. dissertation. University of London: London School of Economics and Political Science.
34. Weiler, J. (1994) 'A quiet revolution: the European Court of Justice and its interlocutors', Comparative Political Studies 26: 510-34.
35. Wilson, J. (1980) 'The politics of regulation', in J.Q Wilson (ed.), The Politics of Regulation, New York: Basic Books Inc.